Anthropic finds itself at the center of a dense news cycle: a U.S. federal appeals court has ruled that the Pentagon may continue to bar the AI company from contracts. At the same time, uncertainty grows around the long-anticipated IPO, investor Joe Lonsdale accuses major tech companies of using safety arguments to control the market—and Anthropic's AI agents report a scientific discovery involving a CRISPR-like enzyme system.
- Federal appeals court upholds the Pentagon's exclusion of Anthropic over safety concerns tied to restrictions on Claude.
- Anthropic's anticipated IPO prospectus (S-1) has still not been filed despite expectations after Labor Day.
- The U.S. government is asking OpenAI and Anthropic to hold back new models from UK testers for now, pending completion of an American review.
- Anthropic investor Joe Lonsdale accuses major tech companies of using safety arguments to exert market control.
- 950 of Anthropic's AI agents have discovered a CRISPR-like enzyme system, according to Forkast.News.
What did the federal appeals court rule in the Anthropic case?
According to The Washington Post and Reuters, a U.S. federal appeals court has ruled that the Pentagon may continue to exclude Anthropic. Reuters describes how the dispute between Anthropic and the Pentagon over AI safety measures tied to restrictions on the use of the Claude model escalated until it landed in court.
Where does Anthropic's anticipated IPO stand?
According to Forkast.News, an S-1 registration form was expected after Labor Day but has still not been filed. Seeking Alpha outlines what investors should know about the Anthropic IPO in 2026 and how they can already gain exposure to the company today via the AI ETF AGIX, while the actual listing remains pending.
Why is Anthropic considered a security risk for the Pentagon according to the court ruling?
The Washington Post and Reuters report that the federal appeals court upheld the Pentagon's assessment that Anthropic is classified as a security risk for government contractors due to restrictions on the use of its Claude model.
What does investor Joe Lonsdale accuse major tech companies of?
According to Open Magazine, Anthropic investor Joe Lonsdale criticizes that safety arguments are being used by tech giants to exert market control rather than genuinely ensuring AI safety.
Alongside the legal dispute, Anthropic is also reporting progress in fundamental research: according to Forkast.News, 950 of the company's AI agents have discovered a CRISPR-like enzyme system—a result the report describes as marking a new frontier in biological research. At the same time, Anthropic is expanding its safety partnerships: Yahoo Finance reports that Accenture has joined Anthropic's AI safety initiative to conduct evaluations of AI systems. In addition, according to Briefs Finance, the U.S. government is requiring OpenAI and Anthropic to hold back new models from UK testers for now, pending completion of an American review.
